Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT01871441 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Trial was closed due to poor accrual.

Conditions

Malignant Neoplasm

Interventions

RADIATION: Total-body irradiation
BIOLOGICAL: Donor lymphocytes infusion (DLI)
DRUG: Cyclophosphamide
PROCEDURE: Allogeneic hematopoietic stem cell transplantation (HSCT)
DRUG: Tacrolimus
DRUG: Mycophenolate mofetil

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University